Sanofi SA reported a strong performance of the specialty medicine Dupixent in the second quarter, a period which also saw the French multinational seal an agreement with GlaxoSmithKline Plc to develop a new vaccine for Covid-19. On 31 July, the two companies announced supply agreements with both the US and the EU for the vaccine, which is based on recombinant protein-based technology developed by Sanofi and adjuvant from GSK.
